These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 18334664

  • 1. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
    Mañosa M, Domènech E, Marín L, Olivé A, Zabana Y, Cabré E, Gassull MA.
    Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
    [No Abstract] [Full Text] [Related]

  • 2. Drug-induced lupus associated with infliximab and adalimumab in an adolescent with Crohn disease.
    Zella GC, Weinblatt ME, Winter HS.
    J Pediatr Gastroenterol Nutr; 2009 Sep; 49(3):355-8. PubMed ID: 19516196
    [No Abstract] [Full Text] [Related]

  • 3. Adalimumab-induced lupus erythematosus with central nervous system involvement in a patient with Crohn's disease.
    Vannucchi V, Grazzini M, Pieralli F, Giannotta M, Biagioni C, Nozzoli C.
    J Gastrointestin Liver Dis; 2011 Jun; 20(2):201-3. PubMed ID: 21725519
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
    Haennig A, Bonnet D, Thebault S, Alric L.
    Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzziello C, Ascolani M, Pallone F, Biancone L.
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L, Laclotte C, Bigard MA.
    Aliment Pharmacol Ther; 2007 Mar 15; 25(6):675-80. PubMed ID: 17311600
    [Abstract] [Full Text] [Related]

  • 10. Transient menorrhagia without adalimumab discontinuation in a patient with Crohn's disease.
    Katsanos KH, Tsianos VE, Tsianos EV.
    J Crohns Colitis; 2010 Sep 15; 4(3):348. PubMed ID: 21122527
    [No Abstract] [Full Text] [Related]

  • 11. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
    Emmert MY, Salzberg SP, Emmert LS, Behjati S, Plass A, Felix C, Falk V, Gruenenfelder J.
    Eur J Heart Fail; 2009 Nov 15; 11(11):1106-9. PubMed ID: 19875411
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab.
    Moss AC, Treister NS, Marsee DK, Cheifetz AS.
    Gastroenterology; 2007 Feb 15; 132(2):488, 829. PubMed ID: 17261307
    [No Abstract] [Full Text] [Related]

  • 14. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
    Verma HD, Scherl EJ, Jacob VE, Bosworth BP.
    J Dig Dis; 2011 Oct 15; 12(5):379-83. PubMed ID: 21955431
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
    van Rijthoven AW, Bijlsma JW, Canninga-van Dijk M, Derksen RH, van Roon JA.
    Rheumatology (Oxford); 2006 Oct 15; 45(10):1317-9. PubMed ID: 16844698
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW, Lawrance IC.
    J Gastroenterol Hepatol; 2009 Jul 15; 24(7):1252-7. PubMed ID: 19220669
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.